Table 3.
Comparison of HE4 and CA125 expression levels and ROMA in ovarian cancer patients with different clinicopathological characteristics
| Clinicopathological characteristics | Case | HE4 (pmol/L) | t | P | CA125 (U/mL) | t | P | ROMA (%) | t | P |
|---|---|---|---|---|---|---|---|---|---|---|
| Age | 1.574 | 0.325 | 5.464 | 0.366 | 4.568 | 0.377 | ||||
| ≥50 years | 29 | 321.01±90.48 | 424.90±107.36 | 69.23±3.17 | ||||||
| <50 years | 21 | 320.01±94.44 | 425.93±108.03 | 71.15±4.02 | ||||||
| Clinical Stages | 2.544 | 0.001 | 3.157 | 0.001 | 3.479 | 0.001 | ||||
| Stage I-II | 40 | 319.01±89.48 | 421.97±107.36 | 65.23±4.32 | ||||||
| Stage III-IV | 10 | 327.91±95.14 | 430.89±111.03 | 76.52±5.28 | ||||||
| Histological grading | 3.774 | 0..002 | 5.475 | 0.001 | 4.562 | 0..002 | ||||
| High differentiation | 15 | 317.01±88.48 | 423.77±106.44 | 63.21±5.02 | ||||||
| Moderate and low differentiation | 35 | 329.91±96.14 | 431.93±131.03 | 75.04±6.27 | ||||||
| Lymph node metastasis | 5.454 | 0.001 | 6.545 | 0.002 | 7.564 | 0.003 | ||||
| Yes | 40 | 333.91±95.12 | 434.43±122.03 | 75.13±5.83 | ||||||
| no | 10 | 316.35±89.56 | 425.77±111.44 | 66.24±6.12 | ||||||